• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.

作者信息

Pervere Leah M, Rakshit Sagar, Schrock Alexa B, Miller Vincent A, Ali Siraj M, Velcheti Vamsidhar

机构信息

Foundation Medicine, Inc, Cambridge, MA.

Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH.

出版信息

Clin Lung Cancer. 2017 May;18(3):e211-e213. doi: 10.1016/j.cllc.2016.11.001. Epub 2016 Nov 11.

DOI:10.1016/j.cllc.2016.11.001
PMID:28024926
Abstract
摘要

相似文献

1
Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.达拉非尼与曲美替尼联合治疗BRAF V600E突变型非小细胞肺癌的持久反应
Clin Lung Cancer. 2017 May;18(3):e211-e213. doi: 10.1016/j.cllc.2016.11.001. Epub 2016 Nov 11.
2
Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.达拉非尼联合曲美替尼治疗 BRAF V600 阳性的晚期或转移性非小细胞肺癌：临床证据和经验。
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618767611. doi: 10.1177/1753466618767611.
3
Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.达拉非尼联合曲美替尼治疗既往未经治疗的 BRAF 突变型转移性非小细胞肺癌的开放标签、2 期临床试验。
Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.
4
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring Mutations.FDA 批准概要：达拉非尼联合曲美替尼治疗携带突变的转移性非小细胞肺癌。
Oncologist. 2018 Jun;23(6):740-745. doi: 10.1634/theoncologist.2017-0642. Epub 2018 Feb 7.
5
Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.BRAF 抑制剂联合或不联合 MEK 抑制剂治疗 BRAF 突变型晚期非小细胞肺癌的疗效和安全性：真实队列研究的结果。
Clin Lung Cancer. 2019 Jul;20(4):278-286.e1. doi: 10.1016/j.cllc.2019.03.007. Epub 2019 Apr 5.
6
Response of BRAF-Mutant Lung Adenocarcinoma With Brain Metastasis and Leptomeningeal Dissemination to Dabrafenib Plus Trametinib Treatment.BRAF 突变型肺腺癌伴脑转移和软脑膜播散对达拉非尼联合曲美替尼治疗的反应
J Thorac Oncol. 2019 May;14(5):e97-e99. doi: 10.1016/j.jtho.2018.12.027.
7
Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation.达拉非尼联合曲美替尼治疗携 BRAF V600E 突变的老年非小细胞肺癌患者。
Thorac Cancer. 2021 Jan;12(2):272-276. doi: 10.1111/1759-7714.13756. Epub 2020 Nov 20.
8
Dabrafenib Active in Rare NSCLC Subtype.达拉非尼在罕见 NSCLC 亚型中有效。
Cancer Discov. 2016 Jul;6(7):OF4. doi: 10.1158/2159-8290.CD-NB2016-062. Epub 2016 May 20.
9
Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.BRAF/MEK 抑制剂对双非 V600E BRAF 突变型肺腺癌的临床疗效：一例报告
Clin Lung Cancer. 2019 May;20(3):e219-e223. doi: 10.1016/j.cllc.2019.02.022. Epub 2019 Mar 4.
10
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.达拉非尼联合曲美替尼与维莫非尼单药治疗不可切除或转移性皮肤 BRAF Val600 突变阳性黑色素瘤患者的健康相关生活质量比较（COMBI-v）：一项开放标签、随机、3 期临床试验结果。
Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X.

引用本文的文献

1
Unique Genomic Alterations of Cerebrospinal Fluid Cell-Free DNA Are Critical for Targeted Therapy of Non-Small Cell Lung Cancer With Leptomeningeal Metastasis.脑脊液游离DNA的独特基因组改变对非小细胞肺癌软脑膜转移的靶向治疗至关重要。
Front Oncol. 2021 Oct 4;11:701171. doi: 10.3389/fonc.2021.701171. eCollection 2021.
2
in Lung Cancers: Analysis of Patient Cases Reveals Recurrent Mutations, Fusions, Kinase Duplications, and Concurrent Alterations.在肺癌中：患者病例分析揭示复发性突变、融合、激酶重复和并发改变。
JCO Precis Oncol. 2018 Apr 19;2. doi: 10.1200/PO.17.00172. eCollection 2018.
3
Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy.
达拉非尼/曲美替尼治疗非小细胞肺癌的聚焦：治疗地位
Cancer Manag Res. 2018 Apr 3;10:647-652. doi: 10.2147/CMAR.S142269. eCollection 2018.
4
Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.达拉非尼联合曲美替尼治疗 BRAF V600 阳性的晚期或转移性非小细胞肺癌：临床证据和经验。
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618767611. doi: 10.1177/1753466618767611.
5
Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism.MEK 抑制剂曲美替尼的心血管作用：病例报告、文献回顾及机制探讨。
Cardiovasc Toxicol. 2017 Oct;17(4):487-493. doi: 10.1007/s12012-017-9425-z.